CN101983628B - 一种美洛西林钠舒巴坦钠药物组合物微球注射剂 - Google Patents
一种美洛西林钠舒巴坦钠药物组合物微球注射剂 Download PDFInfo
- Publication number
- CN101983628B CN101983628B CN2010102463423A CN201010246342A CN101983628B CN 101983628 B CN101983628 B CN 101983628B CN 2010102463423 A CN2010102463423 A CN 2010102463423A CN 201010246342 A CN201010246342 A CN 201010246342A CN 101983628 B CN101983628 B CN 101983628B
- Authority
- CN
- China
- Prior art keywords
- sodium
- microsphere
- mezlocillin
- sulbactam
- sulbactam sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 121
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 title claims abstract description 71
- 229960000614 sulbactam sodium Drugs 0.000 title claims abstract description 71
- KCVTVKMPZQSSNU-UHFFFAOYSA-N 2-pyridin-4-ylethanethioyl chloride Chemical compound ClC(=S)CC1=CC=NC=C1 KCVTVKMPZQSSNU-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960001994 mezlocillin sodium Drugs 0.000 title claims abstract description 69
- 238000002347 injection Methods 0.000 title claims abstract description 41
- 239000007924 injection Substances 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title abstract description 12
- 239000002131 composite material Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 53
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 19
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract description 19
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 19
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 19
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 19
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract description 19
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims abstract description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000007921 spray Substances 0.000 claims description 28
- 239000000890 drug combination Substances 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 18
- 238000001694 spray drying Methods 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 9
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 21
- 238000005516 engineering process Methods 0.000 abstract description 11
- 238000009826 distribution Methods 0.000 abstract description 8
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 5
- -1 poly lactic acid-polyethylene Chemical group 0.000 abstract description 5
- 229940057847 polyethylene glycol 600 Drugs 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- 229960000198 mezlocillin Drugs 0.000 description 8
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 8
- 238000004088 simulation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229960005256 sulbactam Drugs 0.000 description 4
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011805 ball Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000011162 core material Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011806 microball Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 208000007875 Femur Head Necrosis Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BPMFZUMJYQTVII-UHFFFAOYSA-N alpha-guanidinoacetic acid Natural products NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229920006167 biodegradable resin Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229950004403 polifeprosan Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003625 trehaloses Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102463423A CN101983628B (zh) | 2010-08-06 | 2010-08-06 | 一种美洛西林钠舒巴坦钠药物组合物微球注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102463423A CN101983628B (zh) | 2010-08-06 | 2010-08-06 | 一种美洛西林钠舒巴坦钠药物组合物微球注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101983628A CN101983628A (zh) | 2011-03-09 |
CN101983628B true CN101983628B (zh) | 2012-11-21 |
Family
ID=43640791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102463423A Expired - Fee Related CN101983628B (zh) | 2010-08-06 | 2010-08-06 | 一种美洛西林钠舒巴坦钠药物组合物微球注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101983628B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1432361A (zh) * | 2002-01-16 | 2003-07-30 | 山东瑞阳制药有限公司 | 注射用抗生素药物 |
CN1813761A (zh) * | 2005-12-06 | 2006-08-09 | 贵州圣济堂制药有限公司 | 组合粉针剂及其制备方法 |
CN1969846A (zh) * | 2006-04-04 | 2007-05-30 | 陈旭良 | 美西林钠与β-内酰胺酶抑制剂的药物组合 |
CN101322685A (zh) * | 2008-08-01 | 2008-12-17 | 海南百那医药发展有限公司 | 注射用美洛西林钠舒巴坦钠及其冻干粉针剂的制备方法 |
CN101703506A (zh) * | 2009-08-18 | 2010-05-12 | 海南永田药物研究院有限公司 | 一种美洛西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
-
2010
- 2010-08-06 CN CN2010102463423A patent/CN101983628B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1432361A (zh) * | 2002-01-16 | 2003-07-30 | 山东瑞阳制药有限公司 | 注射用抗生素药物 |
CN1813761A (zh) * | 2005-12-06 | 2006-08-09 | 贵州圣济堂制药有限公司 | 组合粉针剂及其制备方法 |
CN1969846A (zh) * | 2006-04-04 | 2007-05-30 | 陈旭良 | 美西林钠与β-内酰胺酶抑制剂的药物组合 |
CN101322685A (zh) * | 2008-08-01 | 2008-12-17 | 海南百那医药发展有限公司 | 注射用美洛西林钠舒巴坦钠及其冻干粉针剂的制备方法 |
CN101703506A (zh) * | 2009-08-18 | 2010-05-12 | 海南永田药物研究院有限公司 | 一种美洛西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101983628A (zh) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2540771A1 (en) | Nanoparticulate therapeutic biologically active agents | |
CN101756908A (zh) | 聚酯包衣的羟基磷灰石微球及其制备方法 | |
CN107375196A (zh) | 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法 | |
CN101890008B (zh) | 一种阿莫西林钠舒巴坦钠药物组合物微球注射剂 | |
CN102727899A (zh) | 载蛋白质类药物的plga复合微球及其制备方法 | |
US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
CN101756910B (zh) | 一种肺靶向头孢噻呋微球及制备方法 | |
WO2005061095A1 (ja) | 微小球体の製造方法およびその製造装置 | |
CN102579365B (zh) | 利培酮微球制剂及其制备方法 | |
CN101890007B (zh) | 一种阿莫西林钠克拉维酸钾药物组合物微球注射剂 | |
CN101773478B (zh) | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 | |
CN106474071A (zh) | 一种空白高分子微球及其制备方法 | |
CN101983629B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 | |
CN101983628B (zh) | 一种美洛西林钠舒巴坦钠药物组合物微球注射剂 | |
CN101966157B (zh) | 一种地西他滨缓释微球及其制备方法 | |
CN101890016B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物微球注射剂 | |
CN101804060B (zh) | 一种头孢曲松钠/他唑巴坦钠药物组合物微球注射剂 | |
CN101912403B (zh) | 一种头孢哌酮钠他唑巴坦钠药物组合物微球注射剂 | |
Galande et al. | A Review on Microspheres: Preparation, Characterization and Applications | |
CN101721376B (zh) | 降钙素缓释微球组合物及其制备方法 | |
CN101618210A (zh) | 一种溶葡萄球菌酶局部缓释制剂及其制备方法和应用 | |
CN104706598B (zh) | 一种隐丹参酮缓释固体分散体微丸的研制及其应用 | |
CN100375635C (zh) | 一种水溶性抗癌药物缓释纤维制剂及其制备方法 | |
CN111991397B (zh) | 一种氟哌噻吨美利曲辛微球及其制备方法 | |
CN101810584B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物微球注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN MEILAN SHIKE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG MING Effective date: 20130724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130724 Address after: 6, No. 570216, Haikou Free Trade Zone, 168 Nanhai Avenue, Hainan, Haikou Patentee after: Hainan Meilan Shike Pharmaceutical Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Wang Ming |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20160806 |